Latest Breaking News On - அணு காரணி - Page 1 : comparemela.com

INDIGO Biosciences Expands Autoimmune-Focused Preclinical Testing Portfolio Share Article Nuclear Factor of Activated T cells Assay Targets Preclinical Autoimmune and Oncology Research The addition of NFAT to our portfolio expands opportunities for autoimmune and oncology researchers to get the critical interaction and activation data they need, before entering costly clinical trials. STATE COLLEGE, Pa. (PRWEB) March 16, 2021 INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include a new Nuclear Factor of Activate T cells (NFAT) assay used primarily for preclinical autoimmune research. This cell-based in vitro assay provides discovery researchers with the ability to quickly make critical decisions about potential drug candidates before moving into trials. NFAT is also implicated in the development of several diseases, including infl

Biosciences incNuclear factor of activateNuclear factorJack vanden heuvelChief scientific officerPress releaseஉயிர் அறிவியல் இன்க்அணு காரணி ஆஃப் செயல்படுத்தஅணு காரணிபலா வாண்டன் ெவேல்தலைமை அறிவியல் அதிகாரிப்ரெஸ் வெளியீடு